Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy — Stella

Home/Opioid Use Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Opioid Use Disorder trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Canada

Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital, Vancouver, British Columbia

Key details

Phase

Safety & dosing

Sponsor

BC Centre on Substance Use

Collaborators

Canadian Institutes of Health Research (CIHR)

Enrollment target

~24 participants

Started

May 2024

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Age range

25 Years and older

Last updated February 2025